COLINZ LABORATORIES LTD.

Company Profile

COLINZ LABORATORIES LTD. had its IPO on under the ticker symbol COLINZ.

The company operates in the sector and industry. COLINZ LABORATORIES LTD. has a staff strength of 0 employees.

Stock update

Shares of COLINZ LABORATORIES LTD. opened at ₹42.7 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹38.7 - ₹42.7, and closed at ₹41.38.

This is a +1.6% increase from the previous day's closing price.

A total volume of 2,798 shares were traded at the close of the day’s session.

In the last one week, shares of COLINZ LABORATORIES LTD. have slipped by -0.17%.

COLINZ LABORATORIES LTD.'s Key Ratios

COLINZ LABORATORIES LTD. has a market cap of ₹92.98 million, indicating a price to book ratio of 1.5122 and a price to sales ratio of 1.7363.

In the last 12-months COLINZ LABORATORIES LTD.’s revenue was ₹0 with a gross profit of ₹48.25 million and an EBITDA of ₹0. The EBITDA ratio measures COLINZ LABORATORIES LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, COLINZ LABORATORIES LTD.’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 578.01%.

In Q2, COLINZ LABORATORIES LTD.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

COLINZ LABORATORIES LTD.’s PE and PEG Ratio

Forward PE

0

Trailing PE

49.7954

PEG

Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into COLINZ LABORATORIES LTD.’s profitability.

COLINZ LABORATORIES LTD. stock is trading at a EV to sales ratio of 0.9946 and a EV to EBITDA ratio of 8.9557. Its price to sales ratio in the trailing 12-months stood at 1.7363.

COLINZ LABORATORIES LTD. stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹102.31 million

Total Liabilities

₹18.86 million

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

COLINZ LABORATORIES LTD. ended 2025 with ₹102.31 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹102.31 million while shareholder equity stood at ₹81.39 million.

COLINZ LABORATORIES LTD. ended 2025 with ₹0 in deferred long-term liabilities, ₹18.86 million in other current liabilities, 25191000.00 in common stock, ₹56.20 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹19.65 million and cash and short-term investments were ₹57.29 million. The company’s total short-term debt was ₹2,734,000 while long-term debt stood at ₹0.

COLINZ LABORATORIES LTD.’s total current assets stands at ₹78.35 million while long-term investments were ₹0 and short-term investments were ₹37.63 million. Its net receivables were ₹11.34 million compared to accounts payable of ₹6.54 million and inventory worth ₹9.39 million.

In 2025, COLINZ LABORATORIES LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, COLINZ LABORATORIES LTD. paid ₹0 in dividends in 2025.

Other key metrics

Current Trading Price

₹41.38

52-Week High

₹61.15

52-Week Low

₹31.6

Analyst Target Price

₹

COLINZ LABORATORIES LTD. stock is currently trading at ₹41.38 per share. It touched a 52-week high of ₹61.15 and a 52-week low of ₹61.15. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹37.74 and 200-day moving average was ₹40.15 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.